Robust Glucose Control and Weight Loss after Six Weeks of Treatment with MEDI0382, a Balanced GLP-1/Glucagon Receptor Dual Agonist, in Patients with Type 2 Diabetes
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes"
DOI: 10.2337/db18-1067-p
Abstract: MEDI0382 is under development for the treatment of type 2 diabetes mellitus (T2DM). In a double-blind study (NCT02548585), 51 T2DM patients with BMI 27-40 kg/m 2 were randomized (1:1) to daily SC MEDI0382 200 μg… read more here.
Keywords: employee; self astrazeneca; self; employee self ... See more keywords
Impact of SGLT2 Inhibitors (SGLT2i) on Cardiovascular (CV) Risk and Estimated Glomerular Filtration Rate (eGFR) in the EXSCEL Placebo Group
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes"
DOI: 10.2337/db18-130-lb
Abstract: SGLT2i, empagliflozin and canagliflozin, have been shown to reduce the incidence of major adverse CV events (MACE), all-cause mortality (ACM) and renal events in CV outcomes trials (CVOTs), with robust real-world evidence (RWE) suggesting class… read more here.
Keywords: research; self astrazeneca; self; inc ... See more keywords
Vascular Events in Patients with Type 2 Diabetes in the Year following Initiation of Second-Line Therapy-The DISCOVER Study
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes"
DOI: 10.2337/db18-1562-p
Abstract: Background: Vascular complications are the main cause of death and disability in people with type 2 diabetes (T2D). We assessed the occurrence of complication during the first year of follow-up of DISCOVER, a global, observational… read more here.
Keywords: self astrazeneca; support self; research support; ltd ... See more keywords
Absence of Changes in Galectin-3 with Insulin Sensitization and Anti-inflammation
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes"
DOI: 10.2337/db18-1771-p
Abstract: Galectin-3 (gal-3) has recently been shown to mediate insulin resistance in mice. Its deletion leads to insulin sensitization while its excess is associated with insulin resistance. We, thus, undertook an investigation into its role in… read more here.
Keywords: self astrazeneca; absence changes; insulin resistance; insulin sensitization ... See more keywords
MEDI0382, a GLP-1/Glucagon Receptor Dual Agonist, Dramatically Reduces Hepatic Collagen in a Mouse Model of NASH
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes"
DOI: 10.2337/db18-1841-p
Abstract: Nonalcoholic steatohepatitis (NASH), characterized by hepatic steatosis, inflammation and fibrosis is an unmet medical need. MEDI0382, a balanced GLP-1/glucagon dual receptor agonist, is under development for the treatment of T2DM. Here we examined the effects… read more here.
Keywords: glp glucagon; self astrazeneca; self; medi0382 ... See more keywords
1279-P: Socioeconomic Factors Associated with Poor Glycemic Control in People with Type 2 Diabetes: The DISCOVER Study
Sign Up to like & getrecommendations! Published in 2019 at "Diabetes"
DOI: 10.2337/db19-1279-p
Abstract: Background: DISCOVER is a 3-year, observational study of patients with type 2 diabetes (T2D) initiating second-line glucose-lowering therapy in 38 countries. We assessed socioeconomic factors associated with poor glycemic control (HbA1c ≥ 9.0%) at baseline.… read more here.
Keywords: novo nordisk; ltd; self astrazeneca; company ... See more keywords
1112-P: Does Background T2D Therapy Modify the Benefits of Dapagliflozin in Heart Failure? Analysis of the DAPA-HF Trial
Sign Up to like & getrecommendations! Published in 2020 at "Diabetes"
DOI: 10.2337/db20-1112-p
Abstract: Background: At present, dapagliflozin (dapa) is typically used as a 2nd-line glucose-lowering medication (GLM) in T2D, often added to metformin. In DAPA-HF, dapa improved clinical outcomes vs. placebo in patients (pts) with HF and reduced… read more here.
Keywords: t2d; self astrazeneca; pharmaceuticals inc; self ... See more keywords
89-LB: The Effect of GIP on Plasma Glucose in a Setting of Prandial Insulin Overdose and Physical Activity after Meal Intake in Patients with Type 1 Diabetes
Sign Up to like & getrecommendations! Published in 2020 at "Diabetes"
DOI: 10.2337/db20-89-lb
Abstract: Gluco-regulatory effects of the insulinotropic and glucagonotropic gut hormone glucose-dependent insulinotropic polypeptide (GIP) in type 1 diabetes (T1D) are unclear. We evaluated the effects of exogenous and endogenous GIP on plasma glucose excursions in a… read more here.
Keywords: self astrazeneca; self; gip; novo nordisk ... See more keywords
951-P: Cotadutide (MEDI0382), a Dual Receptor Agonist with Glucagon-Like Peptide-1 and Glucagon Activity, Is Well Tolerated (
Sign Up to like & getrecommendations! Published in 2020 at "Diabetes"
DOI: 10.2337/db20-951-p
Abstract: Background and Aims: Previously, cotadutide demonstrated significant glucose- and body weight-lowering effects in doses up to 300 µg. We examined the safety and efficacy of cotadutide in doses up to 600 µg in patients with… read more here.
Keywords: glucagon; self astrazeneca; self; employee self ... See more keywords
14-OR: Risk of Acute Kidney Injury in Real-World Use of Dapagliflozin
Sign Up to like & getrecommendations! Published in 2021 at "Diabetes"
DOI: 10.2337/db21-14-or
Abstract: A noninterventional postauthorization safety study in adult patients with type 2 diabetes compared the incidence of hospitalized diagnoses of acute kidney injury (hAKI) in new users of dapagliflozin and new users of comparator glucose-lowering drugs… read more here.
Keywords: acute kidney; kidney injury; relationship self; self astrazeneca ... See more keywords